We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc. (“BioDelivery” or the “Company”) (NASDAQ: BDSI), in connection with the proposed acquisition of the Company by Collegium Pharmaceutical, Inc. (“Collegium”) (NASDAQ: COLL) via a tender offer. Under the terms of the acquisition agreement, the Company’s shareholders will receive $5.60 in cash for each share of BioDelivery common stock that they hold. The transaction is valued at approximately $604 million.
WeissLaw LLP is investigating whether (i) BioDelivery’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $5.60 per-share offer price adequately compensates BioDelivery’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, the offer price is below the $7.00 median price target set by analysts following the Company and at least one analyst set a price target for the Company of $10 per share, $4.40 above the per-share offer price.